Drugs / Debio 4228
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06395753 | May 2024 → Jun 2026 overdue | prostate cancer | Debiopharm International SA | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Debio 4228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06395753 ↗ |
| Route | Intramuscular | “Administered as IM injection.” NCT06395753 ↗ |